Anti-neoplastic Agents 2 - Antimetabolites Flashcards
Antimetabolites: Purine Analog - 6-Mercaptopurine (6MP) MOA and Reduce dose when?
Activated by HGPRT to 6-thioinosinic monophosphate –> inhibition of purine nucleotide synthesis
Reduce dose if given with allopurinol
Antimetabolites: Purine Analog - 6-thioguanine (6TG) (1)
No dose modification with allopurinol
Antimetabolites: Pyrimidine Antagonists - 5-fluorouracil (5FU) (MOA (2)
5FU –> Fdump
Inhibits thymidylate synthase –> thymineless death
Antimetabolites: Pyrimidine Antagonists - 5-fluorouracil (5FU) Toxicities (4)
- Nausea
- Mucositis (esophageal ulcers)
- Diarrhea
- Hand and foot syndrome
Antimetabolites: Pyrimidine Antagonists - 5-fluorouracil (5FU) Capecitabine MOA
Convereted to fluorouracil in the tumor
Antimetabolites: Pyrimidine Antagonists - 5-fluorouracil (5FU) Cytarabine Dependent and Use
Highly schedule dependent (S phase)
Used in acute myelogenous leukemia
Antimetabolites: Folate Antagonist - Methotrexate (MTX) MOA (4)
Inhibits dihydrofolate reductase (DHFR)
Tetrahydrofolate not synthesized
Inhibits DNA, RNA, and protein synthesis
Antimetabolites: Folate Antagonist - Normal cells require folic acid, so what do we do?
Leucovorin rescue (folinic acid)
Antidote to methotrexate toxicity
Antimetabolites: Others - Hydroxyurea Use (2)
Used for CML
Used for Sickle Cell Anemia (low dose) –> increase fetal Hbf synthesis
- Antibiotics (Anthracyclines): Doxorubicin and Daunorubicin MOA (3)
- Inhibits topoisomerase II
- Binds to DNA through intercalation blockade of the synthesis of DNA and RNA, and DNA strand scission
- Generation of semiquinone free radicals
- Antibiotics (Anthracyclines): Doxorubicin and Daunorubicin Side Effects (3) and Antidote
- Cardiotoxicity (side effects)
- Acute: pericarditis, arrythmia, ECG changes
- Chronic: CHF
Antidote: Dexrazoxane (prevents CHF) - chelating agent
- Antibiotics (Anthracyclines): Radiation Recall Reaction - Bleomycin MOA
Causes DNA strand scission
- Antibiotics (Anthracyclines): Radiation Recall Reaction - Bleomycin Side effects (2)
- Pulmonary toxicity (pneumonitis with cough, dyspnea, rales, infiltrates)
- Skin (redness, hyperpigmentation, and skin tenderness)
- Mitotic Inhibitors: Vinca Alkaloids MOA (2)
Bind to tubulin: block microtubular polymerization
Cell division is arrested in meta phase
- Mitotic Inhibitors: Vinca Alkaloids - Vinblastine Side Effects (2)
- Bone marrow suppression
2. Alopecia (side effect)
- Mitotic Inhibitors: Vinca Alkaloids - Vincristine Side Effects (1)
Peripheral neuropathy
- Mitotic Inhibitors: Vinca Alkaloids - Vinorelbine Side Effect (1)
Bone Marrow Suppression
- Mitotic Inhibitors: Taxanes - Paclitaxel (Taxol) MOA
Enhancement of tubulin polymerization
- Mitotic Inhibitors: Taxanes - Paclitaxel (Taxol) Rx of (3)
- Breast cancer
- Lung cancer
- Ovarian cancer
- Mitotic Inhibitors: Taxanes - Docetaxel Rx of (1)
Advanced breast cancer
- Mitotic Inhibitors: Taxanes - Paclitazel and Docetaxel are metabolized by?
Cytochrome P450
- Miscellaneous: Topoisomerase Inhibitors - 2 types and use
- Etopside and Teniposide: lung cancer
2. Irinotecan and Topotecan: colorectal cancer
- Miscellaneous: Enzymes - L-Asparaginase MOA
Catalyses hydrolysis L-asparagine to aspartic acid (tumor cells require L-asparagine for growth)
- Miscellaneous: - L-Asparaginase Side Effects (1)
Pancreatitis
- Miscellaneous: Tyrosine Kinase Inhibitors - Imatinib (GLEEVEC) MOA (2) and Use (1)
Inhibitor of tyrosine kinase domain bcr-able oncoprotein
Prevents the phosphorylation of kinase substrate by ATP
First line therapy in chronic phase of CML and blast crisis
- Miscellaneous: Tyrosine Kinase Inhibitors - Vemurafenib (2)
- B-raf enzyme inhibitor
2. Used in melanoma patients whose cancer has a V600E BRAF mutation
- Miscellaneous: Growth Factor Receptor Inhibitors - Gefitinib (IRESSA) and Erlotinib (TARCEVA) MOA
Inhibitor of the tyrosine kinase domain assoicated with the EGFR (epidermal growth factor receptor)
Used in non-small cell lung cancer
- Miscellaneous: Growth Factor Receptor Inhibitors - Cetuximab (ERBITUX)
EGFR inhibitor used in metastatic colorectal cancer
- Miscellaneous: Growth Factor Receptor Inhibitors - Rituximab (RITUXAN) Target and Use (2)
Attacks CD20
Used in B cell lymphoma
- Miscellaneous: Growth Factor Receptor Inhibitors - Trastuzamab (HERCEPTIN) Target and Use
HER2/Neu (ErbB-2)
Used in breast cancer
- Miscellaneous: Growth Factor Receptor Inhibitors - Lapatinib (TYKERB) Chemo protocols
Hodgkin’s Disease: ABVD region
Adriamycin (doxorubicin)
Bleomycin
Vinblastine
Dacarbazine
Resistance to Chemotherapy: Formation of cancer drug inactivating enzymes
6-mercaptopurine and 5-FU
Resistance to Chemotherapy: Decrease of binding affinity and drug sensitivty (4)
- Etoposide
- Methotrexate
- Vincristine
- Vinblastine
Resistance to Chemotherapy: Decrease drug accumulation or permeability (3)
- Methotrexate
- Dactinomycin
- Cyclophosphamide
Resistance to Chemotherapy: Chemical Reactions Inactivating Chemotherapy (3)
- Cyclophosphamide
- Bleomycin
- Cisplatin
Resistance to Chemotherapy: Increased nucleic acid repair mechanism (2)
- Cisplatin
2. Cyclophosphamide
Resistance to Chemotherapy: Reduced activation of pro-drgs 2)
- 6-mercaptopurine
2. 5 FU
Resistance to Chemotherapy: Multdrug resistances MOA (2)
- Increased expression of MDR1 gene for P-glycoprotein
2. Overexpression of the multidrug resistance protein 1 (MRP1_ t